D. E. Shaw & Co., Inc. - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 128 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2013. The put-call ratio across all filers is 1.26 and the average weighting 0.2%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$15,000
-89.1%
73,331
-76.1%
0.00%
Q3 2018$138,000
-15.3%
307,024
-5.4%
0.00%
Q2 2018$163,000
-79.8%
324,401
-6.2%
0.00%
-100.0%
Q1 2018$806,000
+5.9%
345,985
+29.2%
0.00%0.0%
Q4 2017$761,000
+148.7%
267,731
+149.7%
0.00%
Q3 2017$306,000
+565.2%
107,209
+477.8%
0.00%
Q2 2017$46,000
-78.4%
18,554
-68.6%
0.00%
Q1 2017$213,000
-89.4%
59,000
-89.6%
0.00%
-100.0%
Q4 2016$2,001,000
-55.6%
565,243
-49.3%
0.00%
-62.5%
Q3 2016$4,507,000
+1443.5%
1,115,431
+1578.9%
0.01%
+700.0%
Q2 2016$292,000
-80.2%
66,439
-29.5%
0.00%
-50.0%
Q4 2015$1,477,000
-16.0%
94,220
+35.2%
0.00%
-33.3%
Q2 2015$1,758,000
-40.9%
69,697
-34.7%
0.00%
-40.0%
Q1 2015$2,975,000
-38.3%
106,752
-59.6%
0.01%
-28.6%
Q4 2014$4,823,000
+20.9%
264,283
-14.1%
0.01%
+40.0%
Q3 2014$3,990,000
+21.1%
307,839
+52.5%
0.01%
+25.0%
Q2 2014$3,295,000
+8.2%
201,922
+17.2%
0.00%
-20.0%
Q1 2014$3,044,000
-45.8%
172,215
-25.7%
0.01%
-37.5%
Q4 2013$5,614,000
-2.9%
231,858
+42.2%
0.01%0.0%
Q3 2013$5,779,000
+277.2%
163,100
+66.2%
0.01%
+166.7%
Q2 2013$1,532,00098,1460.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2013
NameSharesValueWeighting ↓
Ridgeback Capital Investments L.P. 1,025,000$24,815,00031.36%
TSP Capital Management Group, LLC 836,342$20,248,0008.80%
Iguana Healthcare Management, LLC 200,000$4,842,0002.76%
First Light Asset Management, LLC 116,096$2,811,0002.38%
SECTORAL ASSET MANAGEMENT INC 2,227,688$53,932,0002.33%
BENNETT LAWRENCE MANAGEMENT L L C/NY 550,735$13,334,0002.05%
Eventide Asset Management 257,000$6,222,0001.92%
Redmile Group, LLC 397,951$9,634,0001.19%
ARDSLEY ADVISORY PARTNERS LP 357,000$8,643,0001.15%
Rhenman & Partners Asset Management AB 90,000$2,179,0000.85%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders